Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of RECCE® 327 for Urinary Tract Infections
26 sept. 2023 08h00 HE
|
Recce Pharmaceuticals
Cohort dosing complete in healthy subjects, with the Phase I/II study on track to meet primary endpointsRECCE® 327 was found to be safe and well-tolerated at a faster infusion rate of 30 minutes of...
Recce Pharmaceuticals Secures $8M Placement and Launches $3M Entitlement Offer to Shareholders
13 sept. 2023 08h00 HE
|
Recce Pharmaceuticals
$8 million commitments received in a strongly supported placement to new and existing institutional investors $3 million entitlement offer at the same offer price as the placementDirectors intend to...
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Vietnam, Strengthening Global IP Portfolio
07 sept. 2023 08h00 HE
|
Recce Pharmaceuticals
SYDNEY, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...
Recce Pharmaceuticals Provides Additional Positive Update on Patients Treated Under “Special Access Scheme”
01 sept. 2023 08h00 HE
|
Recce Pharmaceuticals
RECCE® 327 as a gel formulation (R327G) demonstrated a positive clinical response in the treatment of multiple antibiotic-resistant infections under the Therapeutic Goods Administration (TGA) Special...
Recce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE® 327 at 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
29 août 2023 08h00 HE
|
Recce Pharmaceuticals
Independent Safety Committee approves next cohort dosing of RECCE® 327 (R327) at two faster infusion rates of 3,000mg via IV administrationIndependent Safety Committee unanimously agreed that R327 is...
Recce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE® 327 for Diabetic Foot Infections
24 août 2023 08h00 HE
|
Recce Pharmaceuticals
Patients dosed in Phase I/II trial, evaluating RECCE® 327 (R327) in patients with diabetic foot infections (DFI), currently the largest DFI study in Australia1Clinical trial is underway at South West...
Recce Pharmaceuticals Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections
23 août 2023 08h00 HE
|
Recce Pharmaceuticals
Patients with bacterial infections successfully treated with RECCE® 327 (R327)Deadly bacterial pathogens treated with R327 include those identified by the World Health Organization as major threats to...
Recce Pharmaceuticals Provides Positive Update on Patients Treated with RECCE® 327 Under “Special Access Scheme”
10 août 2023 08h00 HE
|
Recce Pharmaceuticals
RECCE® 327 as a gel formulation (R327G) demonstrated a positive clinical response in the treatment of multiple antibiotic-resistant infections under Therapeutic Goods Administration (TGA) Special...
Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives
04 août 2023 08h00 HE
|
Recce Pharmaceuticals
SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
Recce Pharmaceuticals Receives Second Canadian Scientific Research and Experimental Development Rebate
02 août 2023 08h00 HE
|
Recce Pharmaceuticals
SYDNEY, Australia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...